June 17, 2020 • 1 min read

Consumer Advocates Ask Congress not to Interfere with FDA Regulation of Cannabidiol (CBD)

CFA TC

CFA joined Center for Science in the Public Interest, Consumer Reports, and the Public Health Institute in urging members of Congress to reject proposals to “fast track” the legalization of cannabidiol (CBD) use in dietary supplements and food products. The Food and Drug Administration (FDA) is currently evaluating the safety of CBD, and has made clear that CBD is not “generally recognized as safe” as a food additive, nor approved as dietary supplement. FDA has approved CBD as an approved drug product, and under current regulations, it may not authorize CBD for use in foods and supplements without going through notice and comment rulemaking. The letter urges Congress to give FDA the resources and authority it needs to ensure all dietary supplements and food additives are safe for consumers, and to defer to FDA’s expertise in conducting safety reviews.

Related Articles

CFA TC
October 06, 2026 / Reports
Food Advertising Subsidy Reform: A Win-Win for Fiscal and Public Health
CFA TC
October 06, 2026 / Press Releases
New CFA Report Highlights Opportunity for States to Raise Revenue by Ending Advertising Tax Subsidies for Big Food
CFA TC
September 21, 2026 / Blogs
Food Safety and Corruption
CFA TC
September 14, 2026 / Blogs
Why Country of Origin Labeling Matters